Stockreport

BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025

BeOne Medicines Ltd. - American Depositary Shares  (ONC) 
PDF BRUKINSA now demonstrates best-in-class sustained efficacy and long-term benefit with a favorable safety profile over more than six years of follow-up data in treatment- [Read more]